Clik here to view.
GeneNews JV in U.S.-wide rollout of ColonSentry, adds new test
GeneNews’ (TSX:GEN) recently formed joint venture, Innovative Diagnostic Laboratory, or IDL, is initiating the full-scale rollout of the ColonSentry test throughout the U.S. and adding EarlyCDT-Lung –...
View ArticleClik here to view.
Zacks ups GeneNews price target to $3
Zacks Investment Research has raised its price target for “outperform-rated” GeneNews (TSX:GEN) to $3 from $2, saying revenue growth will accelerated in 2014 and beyond from a recently formed U.S....
View ArticleClik here to view.
GeneNews’ JV IDL launches Beckman Coulter’s phi test across U.S.
GeneNews’ (TSX:GEN) recently formed joint venture, Innovative Diagnostic Laboratory, has added Beckman Coulter Diagnostics’ Prostate Health Index (phi) to its menu of advanced cancer assays and has...
View ArticleClik here to view.
GeneNews IDL JV posts big jumps in tests processed
GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), has reported a 346% sequential jump in tests processed during the first quarter, compared with the 2013...
View ArticleClik here to view.
GeneNews’ IDL off to flying start
GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), took a huge step forward in the first quarter in its goal of becoming a leader in molecular diagnostics...
View ArticleClik here to view.
GeneNews’ IDL jv highlighted on CEO Clips
James Howard-Tripp, executive chairman of GeneNews (TSX:GEN), has been featured on Business Television’s CEO Clips discussing the company’s new U.S. joint venture, Innovative Diagnostic Laboratory, or...
View ArticleClik here to view.
GeneNews Q2 JV lab test volumes more than triple sequentially
GeneNews’ (TSX:GEN) U.S. joint venture, Innovative Diagnostic Laboratory (IDL), processed 46,051 tests in the second quarter, up more than threefold sequentially from the 14,680 tests processed in the...
View ArticleClik here to view.
GeneNews gets promising early results from lung cancer study
GeneNews (TSX:GEN) has received encouraging early results from the largest randomized trial ever conducted for the early detection of lung cancer using EarlyCDT-Lung, an autoantibody biomarker blood...
View ArticleClik here to view.
In conversation with Geoffrey Hamilton-Fairley
Mr. Hamilton-Fairley As CEO of closely-held Oncimmune, an early cancer diagnostic company in Britain, Geoffrey Hamilton-Fairley has had a personal commitment to cancer detection. His father was the...
View Article
